The clinical scenario targeted by dyclonine treatment echoes the pathological aspects of TRPV3-related skin disorders, suggesting that the therapeutic effects of dyclonine might involve its interaction with TRPV3 sensory channel. The gene discussed is TRPV3; the disease is skin disorder.